5-氮杂胞苷作为异基因骨髓移植后复发髓系肿瘤的挽救治疗。
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
机构信息
George W. Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA.
出版信息
Biol Blood Marrow Transplant. 2011 May;17(5):754-8. doi: 10.1016/j.bbmt.2010.10.008. Epub 2010 Oct 15.
Abstract
Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted.
摘要
异基因造血干细胞移植后复发的预后非常差。目前包括供者淋巴细胞输注（DLI）和挽救性化疗在内的治疗策略通常具有毒性且无效。在这里，我们报告了 10 例接受异基因骨髓移植失败后接受 5-氮杂胞苷治疗的骨髓恶性肿瘤患者的结果。在 10 例患者中，6 例达到完全缓解，1 例疾病稳定，3 例在中位数为 6 个周期的治疗后进展。只有 1 例患者（因疾病进展）死亡，并且在使用 5-氮杂胞苷时没有观察到移植物抗宿主病（GVHD）的爆发。截至最新随访，该组的中位总生存期（OS）为 422.5 天（127-1411）。这些结果进一步表明，5-氮杂胞苷是异基因骨髓移植失败后的一种有效药物，需要进行前瞻性研究。
相似文献
1
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.5-氮杂胞苷作为异基因骨髓移植后复发髓系肿瘤的挽救治疗。
Biol Blood Marrow Transplant. 2011 May;17(5):754-8. doi: 10.1016/j.bbmt.2010.10.008. Epub 2010 Oct 15.
2
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
3
T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.T细胞清除联合供体白细胞输注的挽救性免疫疗法作为治疗接受人类白细胞抗原（HLA）相合同胞骨髓移植的慢性期慢性粒细胞白血病患者的一种策略。
Blood. 1999 Jul 15;94(2):434-41.
4
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.供体淋巴细胞输注后使用阿扎胞苷治疗异基因造血干细胞移植后复发的急性髓系白血病的I期研究。
Leuk Res. 2016 Oct;49:1-6. doi: 10.1016/j.leukres.2016.07.010. Epub 2016 Jul 22.
5
Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.非清髓性预处理疗法及 HLA 配型相合供者骨髓移植后，难治性血液系统恶性肿瘤患者混合嵌合体的诱导及抗肿瘤反应的实现。
Biol Blood Marrow Transplant. 2000;6(3A):309-20. doi: 10.1016/s1083-8791(00)70056-5.
6
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.髓系肿瘤移植后复发的治疗：阿扎胞苷和供者淋巴细胞输注作为挽救性治疗。
Leuk Lymphoma. 2019 Nov;60(11):2733-2743. doi: 10.1080/10428194.2019.1605066. Epub 2019 May 3.
7
8
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.在异基因造血干细胞移植后复发的老年急性髓系白血病或慢性粒单核细胞白血病患者中，5-氮杂胞苷 3 天低剂量治疗继以供者淋巴细胞输注的疗效。
Bone Marrow Transplant. 2010 Apr;45(4):627-32. doi: 10.1038/bmt.2009.222. Epub 2009 Aug 31.
9
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation.异基因造血干细胞移植后预防性或抢先性阿扎胞苷治疗髓系肿瘤的耐受性和疗效。
Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):377-382. doi: 10.1016/j.clml.2019.10.011. Epub 2019 Oct 23.
10
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.阿扎胞苷用于异基因造血干细胞移植后复发的单中心研究
Transplant Proc. 2018 Sep;50(7):2212-2217. doi: 10.1016/j.transproceed.2018.02.148. Epub 2018 Mar 14.
引用本文的文献
1
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.阿扎胞苷与供体淋巴细胞输注用于急性髓系白血病及异基因造血干细胞移植后复发的骨髓增生异常综合征，供体为替代供者。
Ther Adv Hematol. 2022 Jun 17;13:20406207221090882. doi: 10.1177/20406207221090882. eCollection 2022.
2
BMT for Myelodysplastic Syndrome: When and Where and How.骨髓增生异常综合征的骨髓移植：时机、地点与方式
Front Oncol. 2022 Jan 6;11:771614. doi: 10.3389/fonc.2021.771614. eCollection 2021.
3
Treatment of AML Relapse After Allo-HCT.异基因造血干细胞移植后急性髓系白血病复发的治疗
Front Oncol. 2021 Dec 16;11:812207. doi: 10.3389/fonc.2021.812207. eCollection 2021.
4
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).一项关于阿扎胞苷联合粒细胞-巨噬细胞集落刺激因子作为维持治疗，用于异基因血液或骨髓移植后高危急性髓系白血病（AML）或骨髓增生异常综合征（MDS）患者的 II 期研究。
Leuk Lymphoma. 2021 Dec;62(13):3181-3191. doi: 10.1080/10428194.2021.1948029. Epub 2021 Jul 21.
5
Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation.阿扎胞苷治疗异基因造血干细胞移植后急性髓系白血病和骨髓增生异常综合征复发的疗效及生存预测
Cancers (Basel). 2020 Aug 12;12(8):2255. doi: 10.3390/cancers12082255.
6
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.用于异基因造血干细胞移植后治疗及预防复发的低甲基化药物。
Int J Hematol. 2018 Feb;107(2):138-150. doi: 10.1007/s12185-017-2364-4. Epub 2017 Nov 15.
7
Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.同种异体减低强度预处理骨髓移植联合移植后环磷酰胺治疗儿科和青年实体肿瘤患者。
Biol Blood Marrow Transplant. 2017 Dec;23(12):2127-2136. doi: 10.1016/j.bbmt.2017.08.012. Epub 2017 Aug 12.
8
Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.低剂量5-氮杂胞苷作为异基因造血干细胞移植后急性髓系白血病和骨髓增生异常综合征复发的预防性治疗。
Bone Marrow Transplant. 2017 Jun;52(6):918-921. doi: 10.1038/bmt.2017.31. Epub 2017 Apr 3.
9
Hypomethylating agents after allogeneic blood stem cell transplantation.异基因造血干细胞移植后的去甲基化药物
Stem Cell Investig. 2016 Nov 28;3:84. doi: 10.21037/sci.2016.11.04. eCollection 2016.
10
Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation.单倍型相合移植与匹配相关或匹配无关造血细胞移植后的复发后生存率。
Bone Marrow Transplant. 2016 Jul;51(7):949-54. doi: 10.1038/bmt.2016.62. Epub 2016 Mar 21.
本文引用的文献
1
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.通过阿扎胞苷和丙戊酸钠联合治疗急性髓系白血病和骨髓增生异常综合征患者诱导对 MAGE 癌症睾丸抗原的 CD8+ T 细胞反应。
Blood. 2010 Sep 16;116(11):1908-18. doi: 10.1182/blood-2009-11-249474. Epub 2010 Jun 8.
2
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.体内给予低甲基化药物可减轻移植物抗宿主病而不牺牲移植物抗白血病。
Blood. 2010 Jul 8;116(1):129-39. doi: 10.1182/blood-2009-12-257253. Epub 2010 Apr 27.
3
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.DNA 去甲基化剂 5-氮杂-2'-脱氧胞苷诱导髓系白血病细胞中 NY-ESO-1 和其他癌/睾丸抗原的表达。
Leuk Res. 2010 Jul;34(7):899-905. doi: 10.1016/j.leukres.2010.02.004. Epub 2010 Apr 10.
4
Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.以5-氮杂胞苷进行供体淋巴细胞输注治疗作为继发于骨髓增生异常综合征的复发急性髓系白血病的挽救治疗。
Anticancer Drugs. 2010 Apr;21(4):469. doi: 10.1097/CAD.0b013e328335be46.
5
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.大剂量环磷酰胺作为单一药物、短疗程预防移植物抗宿主病。
Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2.
6
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.阿扎胞苷相较于传统治疗方案可延长低骨髓原始细胞计数的老年急性髓系白血病患者的总生存期。
J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.
7
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.5-氮杂胞苷（5-azaC）的免疫调节作用：在移植环境中的潜在作用。
Blood. 2010 Jan 7;115(1):107-21. doi: 10.1182/blood-2009-03-210393. Epub 2009 Nov 3.
8
Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine.用 DNA 去甲基化剂 5-氮杂-2'-脱氧胞苷从肿瘤浸润的 CD11b 髓样细胞中生成抗原呈递细胞。
Cancer Immunol Immunother. 2010 May;59(5):697-706. doi: 10.1007/s00262-009-0786-4. Epub 2009 Oct 31.
9
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.在异基因造血干细胞移植后复发的老年急性髓系白血病或慢性粒单核细胞白血病患者中，5-氮杂胞苷 3 天低剂量治疗继以供者淋巴细胞输注的疗效。
Bone Marrow Transplant. 2010 Apr;45(4):627-32. doi: 10.1038/bmt.2009.222. Epub 2009 Aug 31.
10
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.在骨髓恶性肿瘤患者中，5-氮杂胞苷和恩替诺特重叠给药方案中，早期表观遗传变化和DNA损伤无法预测临床反应。
Blood. 2009 Sep 24;114(13):2764-73. doi: 10.1182/blood-2009-02-203547. Epub 2009 Jun 22.
Zotero 插件